Susan Halabi, PhD

Department:
Biostatistics and Bioinformatics

Email Address:
susan.halabi@duke.edu

Address:
Box 2721
DUMC
Durham, NC 27710

Telephone:
9196812224

Fax Telephone:
9196818028

Research Interests:
Design and analysis of clinical trials, survival analysis, statistical analysis of biomarker and microarray data, development and validation of prognostic models.

Publications:
2009 -- Pubmed # 19211452 -- Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ, Chaussade S, Baron JA. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst. 2009 Feb 18;101(4):256-66.

2008 -- Pubmed # 18037582 -- D'Amico AV, Halabi S, Tempany C, Titelbaum D, Philips GK, Loffredo M, McMahon E, Sanford B, Vogelzang NJ, Small EJ,  . Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study.  Int J Radiat Oncol Biol Phys.  2008 May 1;71(1):9-15.

2008 -- Pubmed # 18487572 -- Halabi S, Vogelzang NJ, Kornblith AB, Ou SS, Kantoff PW, Dawson NA, Small EJ. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer.  J Clin Oncol.  2008 May 20;26(15):2544-9.

2008 -- Pubmed # 18172326 -- Kim S, Keku TO, Martin C, Galanko J, Woosley JT, Schroeder JC, Satia JA, Halabi S, Sandler RS. Circulating levels of inflammatory cytokines and risk of colorectal adenomas.  Cancer Res.  2008 Jan 1;68(1):323-8.

2008 -- Pubmed # 18945689 -- Kim S, Martin C, Galanko J, Woosley JT, Schroeder JC, Keku TO, Satia JA, Halabi S, Sandler RS. Use of nonsteroidal antiinflammatory drugs and distal large bowel cancer in whites and African Americans.  Am J Epidemiol.  2008 Dec 1;168(11):1292-300.

2008 -- Pubmed # 18303003 -- Moorman PG, Calingaert B, Palmieri RT, Iversen ES, Bentley RC, Halabi S, Berchuck A, Schildkraut JM. Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women.  Am J Epidemiol.  2008 May 1;167(9):1059-69.

2008 -- Pubmed # 18936475 -- Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.  J Clin Oncol.  2008 Nov 20;26(33):5422-8.

2008 -- Pubmed # 18309951 -- Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M,  . Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.  J Clin Oncol.  2008 Mar 1;26(7):1148-59.

2007 -- Pubmed # 17665494 -- Halabi S, Ou SS, Vogelzang NJ, Small EJ. Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer.  Cancer.  2007 Oct 1;110(7):1478-84.

2007 -- Pubmed # 17404083 -- Ryan CJ, Halabi S, Ou SS, Vogelzang NJ, Kantoff P, Small EJ. Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study.  Clin Cancer Res.  2007 Apr 1;13(7):2030-7.

2006 -- Pubmed # 16753374 -- Halabi S, Vogelzang NJ, Ou SS, Kelly WK, Small EJ. Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies.  J Urol.  2006 Jul;176(1):81-6.

2006 -- Pubmed # 16357602 -- Schildkraut JM, Moorman PG, Halabi S, Calingaert B, Marks JR, Berchuck A. Analgesic drug use and risk of ovarian cancer.  Epidemiology.  2006 Jan;17(1):104-7.

2006 -- Pubmed # 16740791 -- Small EJ, Halabi S, Kantoff P, D'Amico A, Stadler W, Kelley WK, Mohler J, Bajorin D, Vogelzang NJ. Activities and accomplishments of the Cancer and Leukemia Group B Genitourinary Committee.  Clin Cancer Res.  2006 Jun 1;12(11 Pt 2):3596s-600s.

2006 -- Pubmed # 16909426 -- Stadler WM, Halabi S, Rini B, Ernstoff MS, Davila E, Picus J, Barrier R, Small EJ. A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008.  Cancer.  2006 Aug 14.

2005 -- Pubmed # 15756004 -- George DJ, Halabi S, Shepard TF, Sanford B, Vogelzang NJ, Small EJ, Kantoff PW. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: Results from Cancer and Leukemia Group B 9480.  Clin Cancer Res.  2005 Mar 1;11(5):1815-20.

2005 -- Pubmed # 15800342 -- Halabi S, Small EJ, Vogelzang NJ. Elevated body mass index predicts for longer overall survival duration in men with metastatic hormone-refractory prostate cancer.  J Clin Oncol.  2005 Apr 1;23(10):2434-5; author reply 2435.

2005 -- Pubmed # 15802397 -- Moorman PG, Berchuck A, Calingaert B, Halabi S, Schildkraut JM. Antidepressant medication use [corrected] and risk of ovarian cancer.  Obstet Gynecol.  2005 Apr;105(4):725-30.

2005 -- Pubmed # 16299243 -- Ross RW, Halabi S, Ou SS, Rajeshkumar BR, Woda BA, Vogelzang NJ, Small EJ, Taplin ME, Kantoff PW. Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration-resistant prostate cancer--a Cancer and Leukemia Group B study.  Clin Cancer Res.  2005 Nov 15;11(22):8109-13.

2005 -- Pubmed # 16098367 -- Taplin ME, George DJ, Halabi S, Sanford B, Febbo PG, Hennessy KT, Mihos CG, Vogelzang NJ, Small EJ, Kantoff PW. Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study.  Urology.  2005 Aug;66(2):386-91.

2004 -- Pubmed # 15241836 -- Burns CP, Halabi S, Clamon G, Kaplan E, Hohl RJ, Atkins JN, Schwartz MA, Wagner BA, Paskett E. Phase II study of high-dose fish oil capsules for patients with cancer-related cachexia.  Cancer.  2004 Jul 15;101(2):370-8.

2004 -- Pubmed # 15160409 -- Halabi S, Singh B. Sample size determination for comparing several survival curves with unequal allocations.  Stat Med.  2004 Jun 15;23(11):1793-815.

2004 -- Pubmed # 15302462 -- Halabi S, Small EJ, Vogelzang NJ, Barrier RC Jr, George SL, Gilligan TD. Impact of race on survival in men with metastatic hormone-refractory prostate cancer.  Urology.  2004 Aug;64(2):212-7.

2004 -- Pubmed # 15102658 -- Rini BI, Halabi S, Taylor J, Small EJ, Schilsky RL. Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma.  Clin Cancer Res.  2004 Apr 15;10(8):2584-6.

2004 -- Pubmed # 14752077 -- Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis C, Soule HR. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group.  J Clin Oncol.  2004 Feb 1;22(3):537-56.

2004 -- Pubmed # 15020604 -- Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, Gable P, Torti FM, Kaplan E, Vogelzang NJ. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).  J Clin Oncol.  2004 Mar 15;22(6):1025-33.

2003 -- Pubmed # 12560440 -- Halabi S, Small EJ, Hayes DF, Vogelzang NJ, Kantoff PW. Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583.  J Clin Oncol.  2003 Feb 1;21(3):490-5.

2003 -- Pubmed # 12663709 -- Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, Levine EG, Blumenstein BA, Vogelzang NJ. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.  J Clin Oncol.  2003 Apr 1;21(7):1232-7.

2003 -- Pubmed # 12729393 -- Halabi S, Wun CC, Davis BR. Analysis of survival data with missing measurements of a time-dependent binary covariate.  J Biopharm Stat.  2003 May;13(2):253-70.

2003 -- Pubmed # 12646513 -- Lancaster JM, Wenham RM, Halabi S, Calingaert B, Marks JR, Moorman PG, Bentley RC, Berchuck A, Schildkraut JM. No relationship between ovarian cancer risk and progesterone receptor gene polymorphism in a population-based, case-control study in North Carolina.  Cancer Epidemiol Biomarkers Prev.  2003 Mar;12(3):226-7.

2003 -- Pubmed # 14669278 -- Oh WK, Halabi S, Kelly WK, Werner C, Godley PA, Vogelzang NJ, Small EJ. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.  Cancer.  2003 Dec 15;98(12):2592-8.

2003 -- Pubmed # 12621132 -- Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.  N Engl J Med.  2003 Mar 6;348(10):883-90.

2003 -- Pubmed # 12673701 -- Small EJ, Halabi S, Dalbagni G, Pruthi R, Phillips G, Edelman M, Bajorin D. Overview of bladder cancer trials in the Cancer and Leukemia Group B.  Cancer.  2003 Apr 15;97(8 Suppl):2090-8.

2003 -- Pubmed # 12860943 -- Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, Stadler W, Hayes DF, Kantoff PW, Vogelzang NJ, Small EJ. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.  J Clin Oncol.  2003 Jul 15;21(14):2673-8.

2002 -- Pubmed # 11857298 -- Levine EG, Halabi S, Roberts JD, Kaplan EB, Rago R, Atkins JN, Vogelzang NJ. Higher doses of mitoxantrone among men with hormone-refractory prostate carcinoma: a Cancer and Leukemia Group B study.  Cancer.  2002 Feb 1;94(3):665-72.

2002 -- Pubmed # 12084693 -- McBride CM, Bastian LA, Halabi S, Fish L, Lipkus IM, Bosworth HB, Rimer BK, Siegler IC. A tailored intervention to aid decision-making about hormone replacement therapy.  Am J Public Health.  2002 Jul;92(7):1112-4.

2002 -- Pubmed # 11988381 -- Rimer BK, Halabi S, Sugg Skinner C, Lipkus IM, Strigo TS, Kaplan EB, Samsa GP. Effects of a mammography decision-making intervention at 12 and 24 months.  Am J Prev Med.  2002 May;22(4):247-57.

2002 -- Pubmed # 12177096 -- Small EJ, Halabi S, Ratain MJ, Rosner G, Stadler W, Palchak D, Marshall E, Rago R, Hars V, Wilding G, Petrylak D, Vogelzang NJ. Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: Results of intergroup 0159, Cancer and Leukemia Group B 9480.  J Clin Oncol.  2002 Aug 15;20(16):3369-75.

2001 -- Pubmed # 11289126 -- Bok RA, Halabi S, Fei DT, Rodriquez CR, Hayes DF, Vogelzang NJ, Kantoff P, Shuman MA, Small EJ. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: A Cancer and Leukemia Group B study.  Cancer Res.  2001 Mar 15;61(6):2533-6.

2001 -- Pubmed # 11408497 -- Kantoff PW, Halabi S, Farmer DA, Hayes DF, Vogelzang NA, Small EJ. Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer.  J Clin Oncol.  2001 Jun 15;19(12):3025-8.

2001 -- Pubmed # 11331330 -- Savarese DM, Halabi S, Hars V, Akerley WL, Taplin ME, Godley PA, Hussain A, Small EJ, Vogelzang NJ. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.  J Clin Oncol.  2001 May 1;19(9):2509-16.

2001 -- Pubmed # 11430962 -- Schildkraut JM, Cooper GS, Halabi S, Calingaert B, Hartge P, Whittemore AS. Age at natural menopause and the risk of epithelial ovarian cancer.  Obstet Gynecol.  2001 Jul;98(1):85-90.

2000 -- Pubmed # 10636514 -- Schildkraut JM, Halabi S, Bastos E, Marchbanks PA, McDonald JA, Berchuck A. Prognostic factors in early-onset epithelial ovarian cancer: a population-based study.  Obstet Gynecol.  2000 Jan;95(1):119-27.